Dublin, June 06, 2018 (GLOBE NEWSWIRE) -- The "Global Cervical Cancer Screening Market & Patients, by Test Type (Pap Smear, HPV DNA, VIA), 19 Countries Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.
Global Cervical Cancer Screening Market is projected to reach US$ 7 Billion by the year 2024
Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human Papillomavirus (HPV) Virus. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Increasing cervical cancer prevalence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing incidence of HPV infections and increasing awareness about cervical cancer screening programs are also expected to drive the cervical cancer screening market in the near future. The report provides a complete analysis of Global Cervical Cancer Test Market, Screened Population & Mortality. By Test Types - VIA Screening Tests is Gaining Popularity in Developing Countries: The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests, HPV DNA Tests and VIA Tests. Pap smear and HPV DNA tests are more popular with the developed countries such as United States, Germany, United Kingdom and Others. By Region - Asian Region is Expected to Grow Steadily during the Forecast Period: North America and Europe together dominate the Cervical Cancer Screening Market. In addition; the report also provides the complete geographical analysis of Asian and Rest of World, cervical cancer screening market. By Country - Japan is expected to witness a slight decline in Cervical Cancer Screening Market in near Future: The report studies the market/screened population of 19 countries, which provides a complete country-wise analysis of Global Cervical Cancer Screening Market. All the 19 countries are as follows: United Kingdom, India, France, Japan, Italy, China, Sweden, Malaysia, Norway, Canada, Netherlands, Korea, United States, Germany, Switzerland, Singapore, Spain, Thailand and Indonesia
Key Questions Answered in the Report:
- What will be the Cervical Cancer Screening Market by 2024?
- How many women will be screened for Cervical Cancer in the recent future?
- Which country has the maximum and least market share in Cervical Cancer Screening Market?
- What will be the Pap Smear Screening Tests Market by 2024?
- What will be the HPV DNA Screening Tests Market by 2024?
- In which Region, Visual Inspection with Acetic Acid (VIA) Screening Tests is growing.
- How many deaths have occurred due to cervical cancer in each country from 2011 to 2017
Key Topics Covered:
1. Executive Summary 2. Global Cervical Cancer Test (Screening) Population (2011 - 2024) 3. Global Cervical Cancer Test (Screening) Market (2011 - 2024) 3.1 Pap Smear Test (Screening) 3.2 HPV DNA Test (Screening) 3.3 Visual Inspection with Acetic Acid (VIA) Test (Screening) 4. By Region - Global Cervical Cancer Test (Screening) Market Analysis (2011 - 2024) 5. Population Share - Global Cervical Cancer Test (Screening) (2011 - 2024) 5.1 By Region 5.2 By Countries 6. Market Share - Global Cervical Cancer Test (Screening) (2011 - 2024) 6.1 Region - Cervical Cancer Test (Screening) 6.2 Countries - Cervical Cancer Test (Screening) 6.3 Countries - Pap Smear Test (Screening) 6.4 Countries - HPV DNA Test (Screening) 6.5 Countries - VIA Test (Screening) 7. United Kingdom - Cervical Cancer Test Analysis (2011 - 2024) 7.1 Population - Cervical Cancer Test 7.1.1 Pap Smear Test Population 7.1.2 HPV DNA Test Population 7.2 United Kingdom Cervical Cancer Deaths 7.3 Market - Cervical Cancer Test (Screening) 7.3.1 Pap Smear Test Market 7.3.2 HPV DNA Test Market 8. France - Cervical Cancer Test Analysis (2011 - 2024) 8.1 Population - Cervical Cancer Test (Screening) 8.1.1 Pap smear Test Population 8.1.2 HPV DNA Test Population 8.2 France Cervical Cancer Mortality 8.3 Market - Cervical Cancer Test (Screening) 8.3.1 Pap Smear Test Market 8.3.2 HPV DNA Test Market 9. Germany - Cervical Cancer Test Analysis (2011 - 2024) 9.1 Population - Cervical Cancer Test (Screening) 9.1.1 Pap Smear Test Population 9.1.2 HPV DNA Test Population 9.2 Germany Cervical Cancer Mortality 9.3 Market - Cervical Cancer Test (Screening) 9.3.1 Pap Smear Test Market 9.3.2 HPV DNA Test Market & Forecast 10. Italy - Cervical Cancer Test Analysis (2011 - 2024) 10.1 Population - Cervical Cancer Test (Screening) 10.1.1 Pap smear Test Population 10.1.2 HPV DNA Test Population 10.2 Italy Cervical Cancer Mortality 10.3 Market - Cervical Cancer Test (Screening) 10.3.1 Pap Smear Test Market 10.3.2 HPV DNA Test Market 11. Spain - Cervical Cancer Test Analysis (2011 - 2024) 11.1 Population - Cervical Cancer Test (Screening) 11.1.1 Pap Smear Test Population 11.1.2 HPV DNA Test Population 11.2 Spain Cervical Cancer Mortality 11.3 Market - Cervical Cancer Test (Screening) 11.3.1 Pap Smear Test Market 11.3.2 HPV DNA Test Market 12. Sweden - Cervical Cancer Test Analysis 12.1 Population - Cervical Cancer Test (Screening) 12.1.1 Pap smear Test Population 12.1.2 HPV DNA Test Population 12.2 Sweden Cervical Cancer Mortality 12.3 Market - Cervical Cancer Test (Screening) 12.3.1 Pap Smear Test Market 12.3.2 HPV DNA Test Market 13. Switzerland - Cervical Cancer Test Analysis 13.1 Population - Cervical Cancer Test (Screening) 13.1.1 Pap smear Test Population 13.1.2 HPV DNA Test Population 13.2 Switzerland Cervical Cancer Mortality 13.3 Market - Cervical Cancer Test (Screening) 13.3.1 Pap Smear Test Market 13.3.2 HPV DNA Test Market 14. Norway - Cervical Cancer Test Analysis 14.1 Population - Cervical Cancer Test (Screening) 14.1.1 Pap smear Test Population 14.1.2 HPV DNA Test Population 14.2 Norway Cervical Cancer Mortality 14.3 Market - Cervical Cancer Test (Screening) 14.3.1 Pap Smear Test Market 14.3.2 HPV DNA Test Market 15. Netherlands - Cervical Cancer Test Analysis 15.1 Population - Cervical Cancer Test (Screening) 15.1.1 Pap smear Test Population 15.1.2 HPV DNA Test Population 15.2 Netherlands Cervical Cancer Mortality 15.3 Market - Cervical Cancer Test (Screening) 15.3.1 Pap Smear Test Market 15.3.2 HPV DNA Test Market 16. United States - Cervical Cancer Test Analysis 16.1 Population - Cervical Cancer Test (Screening) 16.1.1 Pap smear Test Population 16.1.2 HPV DNA Test Population 16.2 United States Cervical Cancer Mortality 16.3 Market - Cervical Cancer Test (Screening) 16.3.1 Pap Smear Test Market 16.3.2 HPV DNA Test Market 17. Canada - Cervical Cancer Test Analysis 17.1 Population - Cervical Cancer Test (Screening) 17.1.1 Pap smear Test Population 17.1.2 HPV DNA Test Population 17.2 Canada Cervical Cancer Mortality 17.3 Market - Cervical Cancer Test (Screening) 17.3.1 Pap Smear Test Market 17.3.2 HPV DNA Test Market 18. Japan - Cervical Cancer Test Analysis 18.1 Population - Cervical Cancer Test (Screening) 18.1.1 Pap smear Test Population 18.1.2 HPV DNA Test Population 18.2 Japan Cervical Cancer Mortality 18.3 Market - Cervical Cancer Test (Screening) 18.3.1 Pap Smear Test Market 18.3.2 HPV DNA Test Market 19. South Korea - Cervical Cancer Tests Analysis 19.1 Population - Cervical Cancer Test (Screening) 19.1.1 Pap smear Test Population 19.1.2 HPV DNA Test Population 19.2 Korea Cervical Cancer Mortality 19.3 Market - Cervical Cancer Test (Screening) 19.3.1 Pap Smear Test Market 19.3.2 HPV DNA Test Market 20. Singapore - Cervical Cancer Tests Analysis 20.1 Population - Cervical Cancer Test (Screening) 20.1.1 Pap smear Test Population 20.1.2 HPV DNA Test Population 20.2 Market - Cervical Cancer Test (Screening) 20.2.1 Pap Smear Test Market 20.2.2 HPV DNA Test Market 21. Malaysia - Cervical Cancer Test Analysis 21.1 Population - Cervical Cancer Test (Screening) 21.1.1 Pap smear Test Population 21.1.2 HPV DNA Test Population 21.2 Market - Cervical Cancer Test (Screening) 21.2.1 Pap Smear Test Market 21.2.2 HPV DNA Test Market 22. India - Cervical Cancer Test Analysis 22.1 Population - Cervical Cancer Test (Screening) 22.1.1 Pap smear Test Population 22.1.2 HPV DNA Test Population 22.1.3 Cervical Cancer VIA Test Population & Forecast 22.2 Market - Cervical Cancer Test (Screening) 22.2.1 Pap Smear Test Market 22.2.2 HPV DNA Test Market 22.2.3 VIA Test Market & Forecast 23. China - Cervical Cancer Test Analysis 23.1 Population - Cervical Cancer Test (Screening) 23.1.1 Pap smear Test Population 23.1.2 HPV DNA Test Population 23.1.3 Cervical Cancer VIA Test Population & Forecast 23.2 Market - Cervical Cancer Test (Screening) 23.2.1 Pap Smear Test Market 23.2.2 HPV DNA Test Market 23.2.3 VIA Test Market & Forecast 24. Thailand - Cervical Cancer Test Analysis 24.1 Population - Cervical Cancer Test (Screening) 24.1.1 Pap smear Test Population 24.1.2 Cervical Cancer VIA Test Population & Forecast 24.2 Market - Cervical Cancer Test (Screening) 24.2.1 Pap Smear Test Market 24.2.2 VIA Test Market & Forecast 25. Indonesia - Cervical Cancer Test Analysis 25.1 Population - Cervical Cancer Test (Screening) 25.1.1 Pap smear Test Population 25.1.2 HPV DNA Test Population 25.1.3 Cervical Cancer VIA Test Population & Forecast 25.1.4 Indonesia Cervical Cancer Both (Pap smear & VIA) Test Population & Forecast 25.2 Market - Cervical Cancer Test (Screening) 25.2.1 Pap Smear Test Market 25.2.2 HPV DNA Test Market 25.2.3 VIA Test Market 25.2.4 Indonesia Cervical Cancer Both (Pap smear & VIA) Test Market & Forecast 26. Rest of World - Cervical Cancer Test Analysis 26.1 Population - Cervical Cancer Test (Screening) 26.1.1 Pap smear Test Population 26.1.2 HPV DNA Test Population 26.2 Market - Cervical Cancer Test (Screening) 26.2.1 Pap Smear Test Market 26.2.2 HPV DNA Test Market 27. Cervical Cancer Test Market Growth Drivers 27.1 Introduction of Low Cost VIA Test 27.1.1 Countries Offering VIA Test via National Programs 27.1.2 Countries Offering VIA Test via Pilot Programs 27.2 Worldwide High Prevalence of HPV Infected Patients 27.3 Rising Number of Incidence of Cervical Cancer in the United Kingdom 27.4 Worldwide Rising Incidence of Teenage Sexual Cases 28. Challenges in Cervical Cancer Test Market 28.1 Lack of Appropriate Healthcare Infrastructure 28.2 Introduction of HPV Vaccination Programs Worldwide
For more information about this report visit https://www.researchandmarkets.com/research/p...llion?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Diagnostics, Cervical Cancer Drugs , In Vitro Diagnostics
